Terns Pharma successfully shifted its focus after its GLP-1 obesity drug showed underwhelming results. By pivoting to its promising oncology asset for chronic myeloid leukemia, the company dramatically increased its value, culminating in a nearly $7 billion acquisition by Merck. This demonstrates the value of decisively abandoning struggling programs for high-potential ones.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

A Takeda executive compared the potential of its orexin program to the "GLP-1 moment for neuroscience." This framing suggests the drug's mechanism could have broad utility beyond narcolepsy, potentially becoming a foundational platform for numerous neurological disorders, much like GLP-1s transformed metabolic disease.

For an upcoming trial in a new indication, the company is optimistic because its trial design specifically addresses perceived flaws from a competitor's (BMS) similar but unsuccessful study. This demonstrates a sharp R&D strategy that learns from public market failures to de-risk its own pipeline.

When comparing drugs with the same mechanism, like Alkermes' and Takeda's orexin agonists, a wider therapeutic index is a crucial differentiator. This superior safety-to-efficacy ratio allows for higher, more effective dosing without significant side effects, creating a competitive advantage and potential for broader market use.

A decade ago, Neurocrine made the difficult decision to pause development of a promising CRF2 agonist. This ruthless prioritization freed up essential capital and focus to successfully develop what became INGREZZA, their blockbuster drug, demonstrating a long-term strategy of sacrificing a good opportunity for a great one.

Acadia's experimental drug, Remlefanserin, was designed specifically to address the limitations of its marketed drug, Newplazid. By eliminating a side effect (QT prolongation) that capped the dosage of the original drug, the new molecule can be tested at higher, potentially more effective, exposures, demonstrating a strategy of iterative, targeted improvement in drug development.

The CEO's team previously developed Zorampic, which failed commercially due to low efficacy and a kidney toxicity warning. This firsthand experience provided a precise roadmap for their next venture: finding a molecule that was significantly more potent and demonstrably free of the same renal safety liabilities.